Corazon (Corsee) D. Sanders Sells 584 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders sold 584 shares of the business’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $40.98, for a total value of $23,932.32. Following the completion of the transaction, the director now owns 12,009 shares of the company’s stock, valued at approximately $492,128.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $40.21 on Friday. The firm’s 50 day simple moving average is $41.00 and its two-hundred day simple moving average is $44.93. The company has a market capitalization of $3.34 billion, a P/E ratio of -5.01 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million during the quarter, compared to analysts’ expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.33) EPS. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.46 earnings per share for the current fiscal year.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $28,000. UMB Bank n.a. increased its holdings in Ultragenyx Pharmaceutical by 118.8% in the 4th quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 329 shares during the last quarter. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 622.3% in the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 865 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Ultragenyx Pharmaceutical by 34.0% during the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 400 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 3,182.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 1,623 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on RARE shares. Wedbush upped their target price on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, May 31st. Royal Bank of Canada started coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 target price on the stock. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $109.00 to $111.00 and gave the company a “buy” rating in a research note on Friday, May 31st. Bank of America cut their price objective on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating for the company in a report on Friday, May 31st. Finally, Robert W. Baird increased their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the company an “outperform” rating in a report on Friday, May 31st. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $86.71.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.